Availability
in Hospital Keningau
- Cap Fluconazole 50mg & 200mg
- Tab Griseofulvin 125mg
- Cap Itraconazole 100mg
- Tab Ketoconazole 200mg
- Suspension Nystatin 100 000 units/ml
Comparison
of Oral Antifungals
Antifungal
|
Indication
(FUKKM)
|
Pharmacokinetics
|
Ketoconazole
200mg
(B)
|
|
|
Fluconazole
50mg
Fluconazole
100mg
(A)
|
|
|
Itraconazole
100mg
(A/KK)
|
|
|
Voriconazole
200mg
Voriconazole
50mg
(A*)
|
|
|
Syr.
Nystatin
500 000
(B)
|
|
|
Griseofulvin
(B)
|
|
|
Flucytosine
500mg
(A*)
|
|
|
Spectrum
of activity
Imidazole
(Ketoconazole)
- Ketoconazole causes more gastrointestinal disturbances compared to other azoles.
- Has been largely replaced by other triazoles due to favourable pharmacokinetic and safety profile
- Should not be used as first-line treatment for any fungal infection.
- It should be used for the treatment of endemic mycoses (eg, histoplasmosis, blastomycosis) only when alternative antifungal therapies are not available or tolerated.
- Contraindicated in acute or chronic liver disease.
Triazole
(Itraconazole, Fluconazole, Voriconazole)
- The drugs in this class offer activity against many fungal pathogens without the serious nephrotoxic effects observed with amphotericin B
- Due to its inotropic effects, itraconazole’s labeling includes a black box warning in patients with heart failure, particularly in patients receiving a total daily oral dose of 400 mg
Pyrimidine
(Flucytosine)
- Flucytosine has limited clinical indication and is used primarily in combination with Amphotericin B as combination therapy for cryptococcal meningitis and selected life threatening Candida syndromes
References
- Uptodate
- https://mycology.adelaide.edu.au/docs/antifungals.pdf
- https://www.uspharmacist.com/article/the-fungus-among-us-an-antifungal-review
- Lexicomp
- FUKKM
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.